Clinical trials
Obstructive Hypertrophic Cardiomyopathy (oHCM) clinical trials
Below are recruiting obstructive hypertrophic cardiomyopathy (ohcm) clinical trials, each written for real people, not researchers. We’re tracking 8 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Anchorage, AlaskaAges 18 years+ - NCT06023186Recruiting
Effect of mavacamten on heart blood flow in HCM
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
Charlottesville, VirginiaAges 18–85 - NCT07006493Recruiting
Radiofrequency ablation for obstructive hypertrophic cardiomyopathy
This trial tests a new treatment that uses radiofrequency energy (similar to heat) to shrink the thickened heart muscle blocking blood flow. It is for people with obstructive hypertrophic cardiomyopathy who have symptoms despite medication and are not able or willing to have heart surgery.
Beijing, Beijing MunicipalityAges 18–80 - NCT07367724RecruitingPhase 2
Ademetionine for obstructive hypertrophic cardiomyopathy
This trial tests a medication called Ademetionine for people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thick and blocks blood flow). It aims to see if the drug can help improve symptoms and exercise ability.
BeijingAges 18 years+ - NCT07383025Recruiting
Mavacamten safety study for heart muscle disease in Japan
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
TokyoAges 18 years+ - NCT07557498Recruiting
Mavacamten Outcomes and Experiences in Heart Muscle Disease
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
Bollington, MacclesfieldAges 18 years+ - NCT07600177RecruitingPhase 4
Switching Heart Medicines: Mavacamten to Aficamten
This study tests switching from mavacamten to aficamten, two newer medicines that help improve heart function in people with a thickened heart muscle (HCM) that blocks blood flow. The goal is to see if aficamten works as well or better.
Kansas City, MissouriAges 18–90 - NCT07483125Recruiting
Blood pressure drop during Valsalva in hypertrophic cardiomyopathy
This study looks at how blood pressure changes during a simple breathing exercise (the Valsalva maneuver) in people with hypertrophic cardiomyopathy, a condition where the heart muscle is thickened. It aims to understand if this test can help detect a specific type of blockage in the heart's main pumping chamber.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Obstructive Hypertrophic Cardiomyopathy (oHCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for obstructive hypertrophic cardiomyopathy (ohcm)?
- Yes. Clin2 currently lists 8 recruiting obstructive hypertrophic cardiomyopathy (ohcm) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a obstructive hypertrophic cardiomyopathy (ohcm) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a obstructive hypertrophic cardiomyopathy (ohcm) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.